공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

항고혈압제 시장 : 의약품 클래스, 유통채널별 - 세계 시장 기회 분석과 산업 예측(2019-2026년)

Antihypertensive Drugs Market by Therapeutic Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

리서치사 Allied Market Research
발행일 2019년 12월 상품 코드 923993
페이지 정보 영문 222 Pages
가격
US $ 3,840 ₩ 4,264,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 5,769 ₩ 6,407,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,450 ₩ 7,163,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,995 ₩ 9,989,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



항고혈압제 시장 : 의약품 클래스, 유통채널별 - 세계 시장 기회 분석과 산업 예측(2019-2026년) Antihypertensive Drugs Market by Therapeutic Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026
발행일 : 2019년 12월 페이지 정보 : 영문 222 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 항고혈압제 시장은 2018년 225억 5,700만 달러로 평가되었으며, 2019-2026년간 3.1%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 287억 9,700만 달러 규모로 확대될 전망입니다. 세계적인 고혈압 환자수 증가, 고혈압 합병증에 대한 의식 고양, 노인 인구 증가, 신체 활동이 적은 라이프 스타일 등의 요인이 시장 성장을 가속화하고 있습니다.

세계의 항고혈압제(Antihypertensive Drug) 시장을 조사했으며, 시장 개요, 의약품 클래스·최종사용자·지역별 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회, 경쟁 상황, 주요 기업 개요 등의 종합적인 정보를 제공합니다.

목차

제1장 서론

  • 보고서 개요
  • 이해관계자의 주요 이점
  • 주요 시장 부문
  • 조사 방법

제2장 개요

제3장 시장 개요

  • 시장 정의와 범위
  • Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회

제4장 세계의 항고혈압제 시장 : 의약품 클래스별

  • 시장 개요
  • 이뇨제
    • 시장 동향, 성장요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • ACE 억제제
  • 칼슘 길항제
  • 베타 차단제
  • 기타

제5장 세계의 항고혈압제 시장 : 최종사용자별

  • 시장 개요
  • 소매 약국
    • 시장 동향, 성장요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • 병원 약국
  • E-Commerce 웹사이트/온라인 약국

제6장 세계의 항고혈압제 시장 : 지역별

  • 시장 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카

제7장 기업 개요

  • Astrazeneca Plc
  • Boehringer Ingelheim International Gmbh
  • Daiichi Sankyo Company, Limited
  • Johnson & Johnson
  • Lupin
  • Novartis Ag.
  • Merck & Co., Inc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.(Ranbaxy Laboratories)
  • Sanofi
LSH 20.02.28

List of Tables

Table 01. Global Antihypertensive Drugs Market, By Drug Class, 2018-2026 ($Million)

Table 02. Diuretics Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 03. Ace Inhibitors Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 04. Calcium Channel Blockers Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 05. Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 06. Vasodilators Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 07. Others Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 08. Global Antihypertensive Drugs Market, By Distribution Channel, 2018-2026 ($Million )

Table 09. Antihypertensive Drugs Market Revenue For Retail Pharmacy, By Region 2018-2026($Million)

Table 10. Antihypertensive Drugs Market Revenue For Hospital Pharmacy, By Region 2018-2026 ($Million)

Table 11. Antihypertensive Drugs Market Revenue For E-Commerce Websites & Online Drug Stores, By Region 2018-2026 ($Million)

Table 12. Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)

Table 13. North America Antihypertensive Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 14. U.S. Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 15. U.S. Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 16. Canada Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 17. Canada Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 18. Mexico Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 19. Mexico Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 20. North America Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 21. North America Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026($Million)

Table 22. Europe Antihypertensive Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 23. Germany Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 24. Germany Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 25. France Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 26. France Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 27. Uk Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 28. Uk Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 29. Italy Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 30. Italy Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 31. Rest of Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 32. Rest of Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 33. Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 34. Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026($Million)

Table 35. Asia-Pacific Antihypertensive Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 36. Japan Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 37. Japan Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 38. China Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 39. China Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 40. India Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 41. India Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 42. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 43. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 44. Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 45. Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026($Million)

Table 46. Lamea Antihypertensive Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 47. Brazil Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 48. Brazil Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 49. South Africa Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 50. South Africa Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 51. Saudi Arabia Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 52. Saudi Arabia Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 53. Rest of Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 54. Rest of Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 ($Million)

Table 55. Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 56. Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026($Million)

Table 57. Astrazeneca: Company Snapshot

Table 58. Astrazeneca: Operating Business Segments

Table 59. Astrazeneca: Product Portfolio

Table 60. Boehringer Ingelheim: Company Snapshot

Table 61. Boehringer Ingelheim: Product Business Segments

Table 62. Boehringer Ingelheim: Product Portfolio

Table 63. Daiichi-Sankyo.: Company Snapshot

Table 64. Daiichi-Sankyo.: Operating Business Segments

Table 65. Daiichi-Sankyo.: Product Portfolio

Table 66. J&J: Company Snapshot

Table 67. J&J: Operating Business Segments

Table 68. J&J: Product Portfolio

Table 69. Lupin: Company Snapshot

Table 70. Lupin: Operating Segments

Table 71. Lupin: Product Portfolio

Table 72. Novartis: Company Snapshot

Table 73. Novartis: Operating Business Segments

Table 74. Novartis: Product Portfolio

Table 75. Merck: Company Snapshot

Table 76. Merck: Operating Segments

Table 77. Merck: Product Portfolio

Table 78. Pfizer: Company Snapshot

Table 79. Pfizer: Operating Segments

Table 80. Pfizer: Product Portfolio

Table 81. Sun Pharma: Company Snapshot

Table 82. Sun Pharma: Product Portfolio

Table 83. Sanofi: Company Snapshot

Table 84. Sanofi: Product Portfolio

List of Figures

Figure 01. Global Antihypertensive Drugs Market Segmentation

Figure 02. Top Player Positioning, 2018

Figure 03. Top Investment Pockets

Figure 04. Moderate Bargaining Power of Supplier

Figure 05. Low Bargaining Power of Buyers

Figure 06. Low Threat of Substitutes

Figure 07. High Intensity of Rivalry

Figure 08. Low Threat of New Entrant

Figure 09. World Population Aged 65 And Over (%)

Figure 10. Impact Analyses, Antihypertensive Drugs Market

Figure 11. Comparative Share Analysis of Diuretics Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Ace Inhibitors Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Calcium Channel Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Vasodilators Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Share Analysis of Others Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 17. Comparative Share Analysis of Antihypertensive Drugs Market For Retail Pharmacy, By Country, 2018 & 2026 (%)

Figure 18. Comparative Share Analysis of Antihypertensive Drugs Market For Hospital Pharmacy, By Country, 2018 & 2026 (%)

Figure 19. Comparative Share Analysis of Antihypertensive Drugs Market For E-Commerce Websites & Online Drug Stores, By Country, 2018 & 2026 (%)

Figure 20. U.S. Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 21. Canada Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 22. Mexico Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 23. Comparison of Male Geriatric Population In European Countries, 2017 (Million)

Figure 24. Germany Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 25. France Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 26. Uk Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 27. Italy Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 28. Rest of Europe Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 29. Japan Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 30. China Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 31. India Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 32. Rest of Asia-Pacific Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 33. Brazil Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 34. South Africa Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 35. Saudi Arabia Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 36. Rest of Lamea Antihypertensive Drugs Market, 2018-2026 ($Million)

Figure 37. Astrazeneca: Net Sales, 2016-2018 ($Million)

Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 39. Boehringer Ingelheim: Net Sales, 2016-2018 ($Million)

Figure 40. Boehringer Ingelheim: Revenue Share By Segment, 2018 (%)

Figure 41. Boehringer Ingelheim: Revenue Share By Region, 2018(%)

Figure 42. Daiichi-Sankyo: Net Sales, 2016-2018 ($Million)

Figure 43. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)

Figure 44. Daiichi-Sankyo: Revenue Share By Region, 2018(%)

Figure 45. J&J: Net Sales, 2016-2018 ($Million)

Figure 46. J&J: Revenue Share By Segment, 2018 (%)

Figure 47. J&J: Revenue Share By Region, 2018(%)

Figure 48. Lupin: Net Sales, 2017-2019 ($Million)

Figure 49. Lupin: Revenue Share By Region, 2019(%)

Figure 50. Novartis Ag: Net Sales, 2016-2018 ($Million)

Figure 51. Novartis Ag: Revenue Share By Segment, 2018 (%)

Figure 52. Novartis Ag: Revenue Share By Geography, 2018 (%)

Figure 53. Merck: Net Sales, 2016-2018 ($Million)

Figure 54. Merck: Revenue Share By Segment, 2018 (%)

Figure 55. Merck: Revenue Share By Region, 2018(%)

Figure 56. Pfizer: Net Sales, 2016-2018 ($Million)

Figure 57. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 58. Pfizer: Revenue Share By Region, 2018(%)

Figure 59. Sun Pharma: Net Sales, 2016-2018 ($Million)

Figure 60. Sun Pharma: Revenue Share By Region, 2018(%)

Figure 61. Sanofi: Net Sales, 2016-2018 ($Million)

Figure 62. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 63. Sanofi: Revenue Share By Region, 2018(%)

The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs. Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators. These drugs are prescribed by a physician, and are available in retail stores and hospital pharmacies.

The growth of the global antihypertensive market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is another major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle act as key drivers of the global market. However, recent patent expirations hinder the growth of the antihypertensive market. Conversely, surge in research related to antihypertensive drugs in emerging economies is expected to offer lucrative opportunities during the forecast period.

The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Therapeutic Class

Diuretics

ACE Inhibitors

Calcium Channel Blockers

Beta-adrenergic Blockers

Vasodilators

Others

By Distribution Channel

Retail Pharmacy

Hospital Pharmacy

E-commerce

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

List of key players profiled in the report

Boehringer Ingelheim GmbH

Merck KGaA

Johnson and Johnson

Bayer AG

Pfizer, Inc.

Takeda Pharmaceutical Co., Ltd.

AstraZeneca plc

Daiichi Sankyo Company

Sanofi S.A.

Novartis International AG

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

Merck

United Therapeutics Corporation Safe In Breastfeeding

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Market Segments
    • 1.2.1. List of Key Players Profiled In The Report
  • 1.3. Research Methodology
    • 1.3.1. Primary Research
    • 1.3.2. Secondary Research
    • 1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Key Findings of The Study
  • 2.2. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Top Player Positioning
    • 3.2.1. Top Investment Pockets
  • 3.3. Key Forces Shaping Antihypertensive Industry/Market
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge In Geriatric Population Worldwide
      • 3.4.1.2. Surge In Healthcare Expenditure Worldwide
      • 3.4.1.3. Rise In Prevalence of Hypertension Across The Globe
    • 3.4.2. Restraint
      • 3.4.2.1. Patent Expirations of Blockbuster Drugs
    • 3.4.3. Opportunity
      • 3.4.3.1. High Growth Potential In Developing Economies
    • 3.4.4. Impact Analyses

Chapter 4: Antihypertensive Drugs Market, By Drug Class

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Diuretics
    • 4.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.2.2. Market Size And Forecast, By Region
    • 4.2.3. Market Analysis By Country
  • 4.3. Ace Inhibitors
    • 4.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.3.2. Market Size And Forecast, By Region
    • 4.3.3. Market Analysis By Country
  • 4.4. Calcium Channel Blockers
    • 4.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.4.2. Market Size And Forecast, By Region
    • 4.4.3. Market Analysis By Country
  • 4.5. Beta-Adrenergic Blockers
    • 4.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.5.2. Market Size And Forecast, By Region
    • 4.5.3. Market Analysis By Country
  • 4.6. Vasodilators
    • 4.6.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.6.2. Market Size And Forecast, By Region
    • 4.6.3. Market Analysis By Country
  • 4.7. Others
    • 4.7.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.7.2. Market Size And Forecast, By Region
    • 4.7.3. Market Analysis By Country

Chapter 5: Antihypertensive Drugs Market, By End User

  • 5.1. Overview
    • 5.1.1. Market Size And Forecast
  • 5.2. Retail Pharmacy
    • 5.2.1. Market Size And Forecast, By Region
    • 5.2.2. Market Analysis By Country
  • 5.3. Hospital Pharmacy
    • 5.3.1. Market Size And Forecast, By Region
    • 5.3.2. Market Analysis By Country
  • 5.4. E-Commerce Websites & Online Drug Stores
    • 5.4.1. Market Size And Forecast, By Region
    • 5.4.2. Market Analysis By Country

Chapter 6: Antihypertensive Drugs Market, By Region

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast
  • 6.2. North America
    • 6.2.1. Key Market Trends And Opportunities
    • 6.2.2. Market Analysis, By Country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. Market Size And Forecast, By Drug Class
      • 6.2.2.1.2. U.S. Market Size And Forecast, By Distribution Channel
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada Market Size And Forecast, By Drug Class
      • 6.2.2.2.2. Canada Market Size And Forecast, By Distribution Channel
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico Market Size And Forecast, By Drug Class
      • 6.2.2.3.2. Mexico Market Size And Forecast, By Distribution Channel
    • 6.2.3. North America Market Size And Forecast, By Drug Class
    • 6.2.4. North America Market Size And Forecast, By Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key Market Trends And Opportunities
    • 6.3.2. Market Analysis, By Country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany Market Size And Forecast, By Drug Class
      • 6.3.2.1.2. Germany Market Size And Forecast, By Distribution Channel
      • 6.3.2.2. France
      • 6.3.2.2.1. France Market Size And Forecast, By Drug Class
      • 6.3.2.2.2. France Market Size And Forecast, By Distribution Channel
      • 6.3.2.3. Uk
      • 6.3.2.3.1. Uk Market Size And Forecast, By Drug Class
      • 6.3.2.3.2. Uk Market Size And Forecast, By Distribution Channel
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Italy Market Size And Forecast, By Drug Class
      • 6.3.2.4.2. Italy Market Size And Forecast, By Distribution Channel
      • 6.3.2.5. Rest of Europe
      • 6.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class
      • 6.3.2.5.2. Rest of Europe Market Size And Forecast, By Distribution Channel
    • 6.3.3. Europe Market Size And Forecast, By Drug Class
    • 6.3.4. Europe Market Size And Forecast, By Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends And Opportunities
    • 6.4.2. Market Analysis, By Country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan Market Size And Forecast, By Drug Class
      • 6.4.2.1.2. Japan Market Size And Forecast, By Distribution Channel
      • 6.4.2.2. China
      • 6.4.2.2.1. China Market Size And Forecast, By Drug Class
      • 6.4.2.2.2. China Market Size And Forecast, By Distribution Channel
      • 6.4.2.3. India
      • 6.4.2.3.1. India Market Size And Forecast, By Drug Class
      • 6.4.2.3.2. India Market Size And Forecast, By Distribution Channel
      • 6.4.2.4. Rest of Asia-Pacific
      • 6.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
      • 6.4.2.4.2. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel
    • 6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
    • 6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel
  • 6.5. Lamea
    • 6.5.1. Key Market Trends And Opportunities
    • 6.5.2. Market Analysis, By Country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil Market Size And Forecast, By Drug Class
      • 6.5.2.1.2. Brazil Market Size And Forecast, By Distribution Channel
      • 6.5.2.2. South Africa
      • 6.5.2.2.1. South Africa Market Size And Forecast, By Drug Class
      • 6.5.2.2.2. South Africa Market Size And Forecast, By Distribution Channel
      • 6.5.2.3. Saudi Arabia
      • 6.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class
      • 6.5.2.3.2. Saudi Arabia Market Size And Forecast, By Distribution Channel
      • 6.5.2.4. Rest of Lamea
      • 6.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class
      • 6.5.2.4.2. Rest of Lamea Market Size And Forecast, By Distribution Channel
    • 6.5.3. Lamea Market Size And Forecast, By Drug Class
    • 6.5.4. Lamea Market Size And Forecast, By Distribution Channel

Chapter 7: Company Profiles

  • 7.1. Astrazeneca Plc
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Operating Business Segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business Performance
  • 7.2. Boehringer Ingelheim International Gmbh
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Operating Business Segments
    • 7.2.4. Product Portfolio
    • 7.2.5. Business Performance
  • 7.3. Daiichi Sankyo Company, Limited
    • 7.3.1. Company Overview
    • 7.3.2. Operating Business Segments
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Performance
    • 7.3.5. Key Strategic Moves And Developments
  • 7.4. Johnson & Johnson
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Operating Business Segments
    • 7.4.4. Product Portfolio
    • 7.4.5. Business Performance
  • 7.5. Lupin
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Operating Business Segments
    • 7.5.4. Product Portfolio
    • 7.5.5. Business Performance
  • 7.6. Novartis Ag.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Operating Business Segments
    • 7.6.4. Product Portfolio
    • 7.6.5. Business Performance
  • 7.7. Merck & Co., Inc
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Operating Business Segments
    • 7.7.4. Product Portfolio
    • 7.7.5. Business Performance
  • 7.8. Pfizer Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Operating Business Segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business Performance
  • 7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Operating Business Segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business Performance
    • 7.9.6. Key Strategic Moves And Developments
  • 7.10. Sanofi
    • 7.10.1. Company Overview
    • 7.10.2. Operating Business Segments
    • 7.10.3. Product Portfolio
    • 7.10.4. Business Performance
Back to Top
전화 문의
F A Q